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Abstract 
Revisions after total joint replacement increase constantly. In the current study, we analyzed 
clinical outcome, complication rates and cost-effectiveness of revision arthroplasty. In 
retrospective analysis of 162 revision hip and knee arthroplasties from our institutional joint 
registry responder rate, patient-reported outcome measures (EQ-5D, WOMAC), complication 
rates and patient-individual charges in relation to reimbursement were compared with a 
matched control group of primary total joint replacements. Positive responder rate one year 
postoperatively was lower for revision arthroplasties with 72.9% than for primary 
arthroplasties with 90.1% (OR=0.30, 95%CI=0.18–0.59, p=0.001). Correspondingly, 
improvement in patient-reported outcome measures one year after surgery was lower in 
revision than in primary joint arthroplasty with EQ-5D 0.19±0.25 to 0.30±0.24 (p<0.001) and 
WOMAC 24.3±30.3 to 41.2±21.3 (p<0.001). Infection rate was higher in revision (6.8%) 
compared to primary replacements (0%, p=0.001). Mean charges in revision arthroplasty were 
76.0% higher than in matched primary joint replacements (7110.8±2249.4$ to 4041.1±975.7$, 
p<0.001), whereas reimbursement was only 23.6% higher (9243.3±2258.4$ in revision and 
7477.9±703.1$ in primary arthroplasty, p<0.001). Revision arthroplasty is associated with 
lower outcome and higher infection rate compared to primary replacements. The high 
financial expense of revision arthroplasty is only partly covered by a higher reimbursement. 
 
Keywords: Revision Arthroplasty, Outcome, Charges, Reimbursement, Complications 
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Introduction 
In orthopaedic surgery total hip and knee replacements are one of the most successful 
and frequently performed procedures [1]. They represent a curative treatment option of 
advanced hip and knee osteoarthritis with the capacity to substantially improve pain, function 
and quality of life [2]. Despite continuous improvement in surgical technique and implant 
design the number of revision arthroplasty is still expected to grow [3]. By the year 2013 total 
hip and total knee arthroplasty is projected to increase by 137% and 601%, respectively, in the 
United States [4]. The most common reasons for revision total joint arthroplasty reported in 
literature are instability, aseptic loosening and infection [5-7].  
Revision arthroplasty is a complex and challenging procedure. The associated resource 
consumption substantially differs from primary total joint replacements [8]. From a 
socioeconomic point of view the high numbers of revision arthroplasty represent a financial 
burden [3]. As demonstrated in previous studies, the average hospital cost for revision total 
hip arthroplasty have more than tripled within a period of ten years [5, 6, 8]. In literature the 
percentage of patients undergoing revision arthroplasty in relation to primary total joint 
arthroplasties is described as the revision arthroplasty burden [4]. Despite all technical 
progress and surgical efforts this revision burden has not decreased over the past decades [9].  
Independent of financial aspects orthopaedic surgeons aim for the best operative 
treatment in patients undergoing revision arthroplasty. However, a considerable number of 
patients still complain about residual pain and restricted function [10]. Furthermore, revision 
arthroplasty is supposed to be associated with higher postoperative complication rates and 
longer hospital stay [11, 12]. However, advances in joint arthroplasty over the last two 
decades might have reduced complication rates.  
In the current retrospective analysis of 162 revision total hip and knee replacements 
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and corresponding 162 sex, age and ASA (American Society of Anaesthesiologists) class 
matched primary total joint replacements we aimed to investigate responder rate, early clinical 
outcome, complication rates, economic parameters such as operative time and length of 
hospital stay and patient-individual charges in relation to reimbursement at a high volume 
arthroplasty centre. 
 
Patients and Methods   
A retrospective analysis of revision hip and knee replacements and a matched control 
group of corresponding primary replacements from our institutional joint registry was 
performed [13]. The local Ethics Commission waived approval due to the retrospective study 
design. A power calculation was performed for the investigation of the primary endpoint 
positive responder rate after revision total hip and knee arthroplasty. The corresponding 
hypothesis was tested on a 5% significance level. Derived from a previous study [10] and our 
own clinical data the expected difference in responder rates was set to 10%. Based on these 
considerations, a sample size of 151 in each group achieved a power of 80% using two-
sample chi-square test (nQuery Advisor 7.0, Statistical Solutions Ltd, Cork, Ireland). From 
the database 162 patients undergoing all component revision after total hip and knee 
replacement with complete postoperative outcome measures were chosen. Patients with liner 
exchange, soft tissue revision and incomplete data files were excluded. This group was 
matched with a control group of primary total hip and knee replacements according to sex, 
age and ASA class. A total of 162 matched pairs was available for final analysis. All 
operations were performed between January 2012 and December 2016 at our Department of 
Department of Orthopedic Surgery at Regensburg University Medical Centre, Germany. 
Available data from the institutional joint registry included patient age, sex, ASA class, 
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operative procedure, operative time, length of hospital stay, infection rate and pre- and one 
year postoperative Western Ontario and McMaster Universities Arthritis Index (WOMAC) 
[14] and Euro-Quol 5D-5L (EQ-5D) [15]. Using the anonymized case numbers of the registry 
numbers for patient-individual charges such as implant charges, perioperative charges, and 
charges for hospital stay as well as overall reimbursement were available from our financial 
controlling department. The WOMAC is an international widely used score to evaluate 
outcome after total joint replacement representing a multidimensional measure of pain, 
stiffness, and physical functional disability [16]. This measurement of outcomes by health-
related quality of life questionnaire has especially been developed for patients with 
osteoarthritis and has been approved in several longitudinal studies with patients undergoing 
total joint replacement [17-19]. The EQ-5D is a widely used and tested descriptive instrument 
for evaluating health. It defines health based on five dimensions: Mobility, Self-Care, Usual 
Activities, Pain/Discomfort, and Anxiety/Depression. To improve the instrument’s sensitivity 
to small and medium health changes and to reduce ceiling effects the number of levels of 
severity in each dimension was expanded in 2005 to a five-level descriptive system increasing 
reliability and sensitivity of EQ-5D [15]. 
Altogether 94 matched pairs were available for revision hip arthroplasty and 68 for 
revision knee arthroplasty, respectively. Anthropometric characteristics of the study group are 
shown in table 1. Revision total hip arthroplasty in all patients was performed in the supine 
decubitus position using a lateral Hardinge approach. In the control group, a minimally-
invasive single-incision anterolateral approach to the hip was used in terms of an 
intermuscular and interneural tissue plane between the tensor muscle and the gluteus medius 
muscle [20]. Data of the components implanted for revision were not available in our data 
base. For primary cementless total hip arthroplasty press-fit acetabular components and 
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cement-free hydroxyapatite-coated stems of one single manufacturer (Pinnacle®cup, 
Corail®stem or Trilock®stem, DePuy,Warsaw, IN, USA) were used. Both primary and 
revision total knee arthroplasty in all patients was performed through a standard medial 
parapatellar approach including a tourniquet. Data of the components implanted for revision 
were not available in our data base. For primary knees cemented components of one single 
manufacturer (PFC Sigma®, DePuy,Warsaw, IN, USA) were used in all total knee 
replacements. No patella resurfacing was performed.  
For dichotomizing responders and non-responders within the first year after surgery, 
the Outcome Measures in Rheumatology and Osteoarthritis Research Society International 
consensus responder criteria (OMERACT-OARSI) [14, 21] were used as previously described 
[22]. These criteria assess responder status based on relative change in Index (WOMAC) 
scores in relation to benchmarks determined by expert consensus and statistical analyses. 
OMERACT-OARSI criteria were chosen since they do not depend on patient characteristics 
of the cohort and thus reducing any potential selection bias due to the retrospective design of 
the study [23]. The OMERACT-OARSI criteria to assess responders after total joint 
replacement include improvement in pain or function of at least 50% and absolute change of 
at least 20 points. Alternatively, responders are also defined by fulfilment of  two of the 
following criteria: Improvement in pain of at least 20% and absolute change of at least 10 
points, improvement in function of at least 20% and absolute change of at least 10 points, or 
global improvement of at least 20% with absolute change of at least 10 points [21]. 
For statistical analysis, continuous data are presented as mean (standard deviation). 
Group comparisons were performed by two-sided t-tests. Absolute and relative frequencies 
were given for categorical data and compared between groups by chi-square tests. The 
primary hypothesis in the study was tested on 5% significance level. For all secondary 
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hypotheses, significance levels were adjusted according to Bonferroni [24]. Odds ratio (OR) 
and 95% confidence interval (95% CI) were estimated by logistic regression. IBM SPSS 
Statistics 22 (SPSS Inc, Chicago, IL, USA) was used for analysis. 
 
Results   
The positive responder rate as defined by the OMERACT-OARSI criteria [21] within 
the first year after surgery was lower for total revision total hip and knee arthroplasty with 
72.9% (118/162) compared to matched control primary total hip and knee replacements with 
90.1% (146/162, OR = 0.30, 95% CI = 0.18 – 0.59, p=0.001, figure 1). Researching into 
patient-reported outcome measures one year postoperatively WOMAC scores showed a lower 
improvement for revision arthroplasty (24.3 ± 30.3) compared to primary total joint 
arthroplasty (41.2 ± 21.3, p<0.001). Accordingly increase of EQ-5D values one year after 
surgery was lower in the revision group (0.19 ± 0.25) than in the matched control group of 
primary total joint replacements (0.30 ± 0.24, p<0.001, figure 2). Analysing outcome 
measures subscores, again one year results were lower in patients undergoing revision than 
those with primary total joint replacement (table 2). 
Researching into adverse events, we found a higher infection rate in revision (6.8%, 
11/162) compared to primary arthroplasty (0.0%, 0/162, p=0.001), whereas no differences 
were observed regarding intraoperative fractures, thrombosis or neurologic deficits (table 3).  
Mean operative time was 52 minutes longer for revision total joint replacement compared to 
matched primary total hip and knee replacements (127.0 ± 61.3 min versus 74.9 ± 22.6 min, 
p<0.001). Similarly, patients undergoing joint revision had a longer hospital stay of 4 days 
compared to the control group (13.1 ± 6.3 d versus 9.3 ± 1.6 d, p<0.001, figure 3). 
Researching into socioeconomic aspects, revision arthroplasty resulted in a higher financial 
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expense of 76.0% compared with matched primary joint replacements (7110.8 ± 2249.4$ to 
4041.1±975.7$, p<0.001, figure 4). The increased charges in revision arthroplasty were due to 
higher implant costs, perioperative costs and costs of hospital stay (p<0.001). The higher 
reimbursement of 23.6% (9243.3±2258.4$ in revision to 7477.9±703.1$ in primary 
arthroplasty, p<0.001) did only partly cover the elevated costs for revision joint replacements 
(table 4). 
 
Discussion 
Primary total hip and knee arthroplasty is a frequently performed and successful 
procedure in orthopaedic surgery [25]. Correspondingly, number of revision arthroplasty 
increases and is associated with considerable financial expense [3]. In the current matched-
pair study, we aimed to compare (1) responder and early clinical outcome within the first year 
after total joint replacement, (2) complication rate and (3) patient-individual charges in 
relation to reimbursement between revision and primary total hip and knee arthroplasty. We 
found a lower responder rate and lower clinical outcome for revision arthroplasty than for 
matched primary total joint replacements. Infection rate was higher in the revision group. In 
general revision arthroplasty required 52 minutes longer operative time and a prolonged 
hospital stay of 4 days compared to matched primary arthroplasties. In addition to higher 
implant costs this resulted in higher charges of 76.0% compared to primary hip and knee 
replacements. 
There are several limitations of this study. First, the study design is a retrospective 
analysis. Therefore, the results are susceptible to potential bias. We tried to reduce this and 
matched the cohort in terms of age, ASA and sex. To further minimize potential bias we 
chose patient characteristics independent dichotomization for responders. Using non-cohort 
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dependent benchmarks should maximize generalizability. Second, the current study is 
restricted to the information provided by the institutional joint registry. Other parameters such 
as the patient’s psychological or social status might have an impact on the patient specific 
outcome and improve prediction of outcome. Third, for the current analysis only short-term 
outcome data for the first 12 months were available. It would have been of interest to include 
long-term outcome and failure rates. Fourth, we were not able to differentiate between the 
reasons and types of revision surgery. All operations were all component revisions. However, 
this included easier and extraordinary challenging procedures. A strength of the study is the 
fact that all data refer to one single university medical centre reflecting a specific operative 
workflow for total hip and knee replacement as well as an identical postoperative treatment 
protocol for all patients. This contributes to minimizing confounding factors.  
In answer to the first question of the study, we found  an excellent responder rate 
within the first year as defined by the OMERACT-OARSI criteria [21] after primary total hip 
and knee replacement with 90.1%. This is in line with other studies underlining the benefit 
from total joint replacement [1, 2]. In contrast, responder rate in all component revision 
surgery after hip and knee arthroplasty was significantly lower with 72.9%. Similarly, residual 
pain after revision arthroplasty has been described in literature [10]. According to the lower 
responder rate in all component revision total hip and knee arthroplasty, patient reported 
outcome measures as assessed by WOMAC and EQ-5D differed between revision and 
primary total joint replacement one year after surgery. However, the outcome data after 
revision were on a higher level compared to previous data in literature [26]. This demonstrates 
that in modern revision arthroplasty still good outcome is achievable. Overall outcome 
measures for primary total joint replacement in our study were similar to previous published 
early results after total joint replacement of the hip and knee, respectively [27-31]. 
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Furthermore, our data are supported by a previous study showing poorer functional outcome 
for knee replacements compared to hip replacements [32].  
In addition we analysed complication rates after joint replacement since the risk of 
severe adverse events such as infection or fracture has to be considered and balanced with the 
potential benefit of revision arthroplasty. However, except for infection complication rates 
were comparably low for both revision and primary arthroplasty emphasizing revision 
arthroplasty represents a safe procedure in orthopaedic surgery. The observed results are in 
accordance with literature [27, 33, 34]. Regarding infection rate there was markedly higher 
number of infections after revision compared to primary arthroplasty. One reason for this 
higher rate might be due to the fact that revisions due to infection were included in the 
revision cohort. In relation to previous results in literature, the infection rate was still within 
the lower range [35]. No differences between the revision and primary arthroplasty group 
were observed regarding thrombosis and neurological deficits with the numbers available.  
Researching into economic relevant data, mean operative time was 52 minutes longer 
for revision arthroplasties compared to matched primary arthroplasties. The increase in 
operative time was more apparent in hip than in knee revisions compared to matched primary 
total joint replacements. Compared to data from revision arthroplasty two decades ago 
operative times for revision arthroplasty have decreased by 50 percent nowadays [12]. The 
observed operative times for both primary hip and knee replacements were comparable to 
modern literature [27]. From an economic point of view, a prolonged operative time means 
higher financial expense. In addition, mean hospital stay was 4 days longer in our study 
cohort for revision arthroplasty compared to matched primary cases. A prolonged hospital 
stay for revision arthroplasty has been previously reported in literature [36]. This further adds 
costs to the public health care sector as well as higher implant costs resulting in higher 
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procedural charges [3]. In our study cohort charges for revision arthroplasty were 76.0% 
higher compared to primary total joint replacements. In contrast, reimbursement was 23.6% 
higher in revision compared to primary arthroplasty and thus did only partly cover the high 
charges. In addition charges for revision arthroplasty are still rising. In previous studies a 
threefold increase of overall costs for revision hip arthroplasty over the last decade has been 
calculated [6, 8]. Mean annual economic revision burdens of 27% have been reported in 
literature for revision total hip and knee arthroplasties [3]. By 2013 the demand for revision 
hip and knee arthroplasty is expected to substantially grow [4]. Therefore, revision 
arthroplasty of the hip and knee represents a severe challenge for public health care systems. 
On the other hand the increase in outcome after revision might lead to a decrease of costs in 
the period after surgery from the perspective of both patient [18] and public health care [37].   
 
Conclusions 
In conclusion, both hip and knee revision arthroplasty enable patients to regain good 
function and outcome. Still, patients experience lower outcome compared to primary total 
joint replacement. Despite higher infection rates revision arthroplasty is a safe procedure with 
tolerable complication rates. However, revision total hip and knee arthroplasty is cost-
intensive and thus a challenge for public health care. 
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Tables 
Table 1: Anthropometric characteristics of the study group * 
 Hip Revision Hip Primary Knee Revision Knee Primary 
Number of patients 94 94 68 68 
Age (years) 66.9 ± 14.0 66.9 ± 14.0 67.9 ± 9.2 67.9 ± 9.2 
Gender (men/women) 41/53 41/53 26/42 26/42 
ASA-Class 1 12 (12.8%) 12 (12.8%) 3 (4.4%) 3 (4.4%) 
ASA-Class 2 40 (42.6%) 40 (42.6%) 30 (44.1%) 30 (44.1%) 
ASA-Class 3 42 (44.7%) 42 (44.7%) 35 (51.5%) 35 (51.5%) 
* For categorical data values are given as relative and absolute frequencies, for quantitative data values are given 
as mean (standard deviation), ASA = American Society of Anaesthesiologists 
 
Table 2: Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Euro-
Qol 5D-5L (EQ-5D) for revision and primary total hip and knee arthroplasty preoperative and 
1 year after surgery* 
Joint 
replacement 
EQ-5D 
preop 
EQ-5D 
postop 
WOMAC 
preop 
WOMAC 
postop 
Pain 
preop 
Pain 
postop 
Stiffness 
preop 
Stiffness 
postop 
Function 
preop 
Function 
postop 
Hip 
Revision 
mean 0.50 0.71 41.17 68.07 40.00 76.00 44.91 69.68 40.84 65.00 
SD 0.25 0.27 20.43 22.87 23.47 22.72 28.48 22.77 21.07 24.64 
Hip 
Primary 
mean 0.54 0.85 38.06 84.00 36.22 86.28 40.63 81.85 37.83 82.68 
SD 0.24 0.20 17.35 18.36 19.98 17.40 21.63 21.53 18.57 20.06 
p-value 0.45 <0.001 0.37 <0.001 0.31 0.001 0.31 <0.001 0.40 <0.001 
Knee 
Revision 
mean 0.59 0.71 43.41 63.18 40.81 64.93 44.77 61.21 44.32 63.24 
SD 0.20 0.23 14.84 23.62 18.29 25.52 23.02 24.73 15.82 23.67 
Knee mean 0.51 0.78 37.76 70.57 34.14 74.31 36.29 65.00 38.85 69.81 
18 
 
 
Primary SD 0.21 0.19 12.45 19.12 14.32 18.20 21.32 20.52 13.61 19.62 
p-value 0.10 0.08 0.05 0.06 0.04 0.02 0.06 0.34 0.07 <0.10 
* For quantitative data values are given as mean (SD = standard deviation). preop = preoperative. postop = 
postoperative 
 
 
Table 3: Complication rates for revision and primary arthroplasty of the hip and knee * 
Total Joint 
Replacement 
Hip Revision Hip Primary Knee 
Revision 
Knee Primary 
Intraoperative fractures 0.0% (0/94) 1.1 % (1/94) 0.0% (0/68)  0.0% (0/68) 
Thrombosis 0.0% (0/94) 0.0% (0/94) 0.0% (0/68)  0.0% (0/68) 
Neurological deficits 1.1% (1/94) 0.0% (0/94) 0.0% (0/68)  1.5% (1/68) 
Joint infection 5.3% (5/94) 0.0% (0/94) 8.8% (6/68)  0.0% (0/68) 
* For categorical data values are given as relative and absolute frequencies 
Table 4: Financial expense of revision arthroplasty compared to primary joint replacement* 
Cost Analysis Hip Revision Hip Primary Knee Revision Knee Primary 
Implant 2240.5 (1163.7) 978.2 (445.9) 3052.3 (1178.8) 1155.8 (707.9) 
Perioperative  2018.8 (947.6) 1062.1 (327.0) 1755.2 (863.8) 1207.9 (337.7) 
Hospital stay 2649.0 (1183.9) 1849.4 (364.6) 2582.8 (1374.6) 1878.1 (270.3) 
Combined  6908.3 (2312.2) 3889.7 (994.9) 7390.4 (2148.2) 4241.8 (918.3) 
DRG-Income 8920.6 (2084.8) 7225.7 (643.1) 9689.3 (2423.8) 7826.6 (633.4) 
Difference 2012.3 (2576.5) 3336.0 (667.0) 2299.0 (2227.9) 3584.7 (689.2) 
p-value p<0.001 for all variables p<0.001 for all variables 
* For quantitative data values are given as mean (SD = standard deviation). 
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Figures 
Fig. 1 Responder rate as defined by the OMERACT-OARSI criteria [21] one year after 
revision arthroplasty of the hip and knee compared to matched primary hip and knee 
replacements 
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Fig. 2 Improvement of patient reported outcome measures (WOMAC, EQ-5D) within the first 
year after revision total joint arthroplasty 
 
 
Fig. 3 Mean operative time and length of hospital stay of revision total hip and knee 
arthroplasty compared to control group of primary total joint replacements 
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Fig. 4 Distribution of charges for revision total hip and knee arthroplasty compared with 
matched primary total joint replacements 
 
